HK1105886A1 - 含有 的治療癌腫瘤的藥物組合物 - Google Patents

含有 的治療癌腫瘤的藥物組合物

Info

Publication number
HK1105886A1
HK1105886A1 HK08100056.3A HK08100056A HK1105886A1 HK 1105886 A1 HK1105886 A1 HK 1105886A1 HK 08100056 A HK08100056 A HK 08100056A HK 1105886 A1 HK1105886 A1 HK 1105886A1
Authority
HK
Hong Kong
Prior art keywords
treatment
pharmaceutical compositions
cancer tumours
tumours
cancer
Prior art date
Application number
HK08100056.3A
Other languages
English (en)
Inventor
Sez Miguel Muoz
Original Assignee
Antagonista Enekauno S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antagonista Enekauno S L filed Critical Antagonista Enekauno S L
Publication of HK1105886A1 publication Critical patent/HK1105886A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK08100056.3A 2004-02-11 2008-01-03 含有 的治療癌腫瘤的藥物組合物 HK1105886A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200400424A ES2246687B2 (es) 2004-02-11 2004-02-11 Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
PCT/ES2005/000068 WO2005077366A1 (es) 2004-02-11 2005-02-10 Utilización de antagonistas no peptídicos de receptores nk1 para la producción de apoptosis en células tumorales

Publications (1)

Publication Number Publication Date
HK1105886A1 true HK1105886A1 (zh) 2008-02-29

Family

ID=34854896

Family Applications (2)

Application Number Title Priority Date Filing Date
HK08100056.3A HK1105886A1 (zh) 2004-02-11 2008-01-03 含有 的治療癌腫瘤的藥物組合物
HK15102803.6A HK1208192A1 (zh) 2004-02-11 2015-03-18 採用非肽 受體拮抗劑形成腫瘤細胞凋亡

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15102803.6A HK1208192A1 (zh) 2004-02-11 2015-03-18 採用非肽 受體拮抗劑形成腫瘤細胞凋亡

Country Status (12)

Country Link
US (4) US9867814B2 (zh)
EP (2) EP1803456B1 (zh)
AU (1) AU2005211955B2 (zh)
CA (1) CA2566315C (zh)
CY (1) CY1116415T1 (zh)
DK (1) DK1803456T5 (zh)
ES (2) ES2246687B2 (zh)
HK (2) HK1105886A1 (zh)
PL (1) PL1803456T3 (zh)
PT (1) PT1803456E (zh)
SI (1) SI1803456T1 (zh)
WO (1) WO2005077366A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246687B2 (es) 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
WO2009124756A1 (en) * 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Use of aprepitant and derivatives thereof for the treatment of cancer
ES2376564B1 (es) 2010-08-12 2013-01-24 Manuel Vicente Salinas Martín Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
EP2837381A4 (en) 2011-12-13 2015-12-09 Servicio Andaluz De Salud USE OF AGENTS MODIFYING THE PERITUMORAL ENVIRONMENT FOR THE TREATMENT OF CANCER
ES2493693B1 (es) * 2013-02-11 2015-07-07 Servicio Andaluz De Salud Método para predecir o pronosticar la respuesta de un sujeto humano que padece un cáncer al tratamiento con un antagonista del receptor NK1
ES2541870B1 (es) 2013-12-27 2016-05-12 Servicio Andaluz De Salud Uso de antagonistas no peptídicos de NK1 en una determinada dosis para el tratamiento del cáncer
US20160324881A1 (en) * 2013-12-30 2016-11-10 Oncoprevent Gmbh Neurokinin-1 Receptor Antagonists For Use In A Method Of Prevention Of Cancer
WO2015166128A1 (es) * 2014-04-29 2015-11-05 Servicio Andaluz De Salud Método para diagnosticar y monitorizar la presencia de cáncer en un sujeto humano.
CA2956022A1 (en) * 2014-07-24 2016-01-28 Plus Vitech,S.L Neurokinin-1 receptor antagonist composition for treatment of diseases and conditions of the respiratory tract
ES2595442B1 (es) * 2015-05-27 2017-10-04 Consejo Superior De Investigaciones Cientificas (Csic) Antagonistas de los receptores nk1 derivados de hidratos de carbono, metodo de obtencion y uso medico
WO2024069344A1 (en) * 2022-09-29 2024-04-04 Keyzell Holding S.L. Compositions for the treatment and prevention of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680283A (en) 1984-09-26 1987-07-14 Merck & Co., Inc. Analogs of substance P and eledoisin
CA2106874A1 (en) * 1991-04-22 1992-10-29 Theofilus J. Visser Method for detecting and localizing tissues having neurokinine 1 receptors
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
SK283070B6 (sk) 1993-12-29 2003-02-04 Merck Sharp & Dohme Limited Substituované morfolínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
CA2189501A1 (en) * 1995-11-06 1997-05-07 Harry R. Howard Nk-1 receptor antagonists for the treatment of cancer
US6037340A (en) * 1997-05-28 2000-03-14 Cadus Pharmaceutical Corporation Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
IT1306165B1 (it) * 1999-07-05 2001-05-30 Innova Ltd Impiego di inibitori della sostanza p per il trattamento degliadenocarcinomi.
US20010034320A1 (en) * 2000-01-18 2001-10-25 Hans-Michael Brecht NK1-receptor antagonists for treating restless legs syndrome
DE60112064T2 (de) 2000-04-10 2006-06-01 Pfizer Products Inc., Groton Benzoamid-piperidin verbindungen als substanz p-antagonisten
CN100398106C (zh) * 2001-04-23 2008-07-02 弗·哈夫曼-拉罗切有限公司 Nk-1受体拮抗剂对抗良性前列腺增生的用途
US6713490B2 (en) * 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
US20050227929A1 (en) * 2003-11-13 2005-10-13 Masferrer Jaime L Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
EP1874339A1 (en) 2005-04-21 2008-01-09 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
WO2009124756A1 (en) * 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Use of aprepitant and derivatives thereof for the treatment of cancer

Also Published As

Publication number Publication date
US9867814B2 (en) 2018-01-16
US20090012086A1 (en) 2009-01-08
HK1208192A1 (zh) 2016-02-26
US20180117027A1 (en) 2018-05-03
PT1803456E (pt) 2015-03-04
EP2842605A2 (en) 2015-03-04
WO2005077366A1 (es) 2005-08-25
ES2246687B2 (es) 2006-11-16
CY1116415T1 (el) 2017-02-08
AU2005211955B2 (en) 2011-06-23
WO2005077366B1 (es) 2005-09-15
PL1803456T3 (pl) 2015-08-31
DK1803456T3 (en) 2015-03-02
EP2842605A3 (en) 2015-03-18
DK1803456T5 (da) 2015-06-22
ES2535184T3 (es) 2015-05-06
CA2566315A1 (en) 2005-08-25
EP1803456B1 (en) 2014-11-26
EP1803456A1 (en) 2007-07-04
CA2566315C (en) 2013-08-27
SI1803456T1 (sl) 2015-05-29
US20150224095A1 (en) 2015-08-13
ES2246687A1 (es) 2006-02-16
AU2005211955A1 (en) 2005-08-25
US20200054620A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
HK1105886A1 (zh) 含有 的治療癌腫瘤的藥物組合物
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
HK1102544A1 (en) Use of herbal compositions in the manufacture of medicine for treating prostate cancer
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
PL2601961T3 (pl) Kompozycje zawierające LAG-3 i terapeutyczne przeciwciała oraz ich zastosowania w leczeniu raka
ZA200805163B (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
IL218317A (en) Use of 15-il polypeptide preparations and 15-il complexes for the preparation of cancer drugs
IL191938A (en) The ovarian heterocellular compounds, pharmaceuticals containing them, and the ovarian heterocellular compounds for cancer treatment
HK1136822A1 (en) Therapeutic compounds and their use in cancer
PL1765391T3 (pl) Kompozycje bakteryjne do leczenia nowotworów
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
EP1812596A4 (en) TREATMENT OF CANCER AND COMPOSITIONS
GB2453011B (en) Antifolate agent compositions in the treatment of cancer
IL178939A (en) Double and triple combinations suitable for synergistic treatment of breast cancer, including pharmaceuticals and their use in the manufacture of drugs and drugs for the treatment of breast cancer
HK1100484A1 (en) Application of n-butylidenephthalide in preparing cancer treatment medication
LT2340872T (lt) Naujos farmacinės kompozicijos, naudingos nemigos gydyme
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
HK1111599A1 (en) Pharmaceutical compositions for the treatment of cellulite
ZA200701578B (en) Combination anticancer therapy and pharmaceutical compositions therefore
ZA200709542B (en) Combination therapy in the treatment of cancer
EP1904088A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
GB0619816D0 (en) Novel interferon-alpha constructs for use in the treatment of cancer
EP1797430A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER
IL175774A0 (en) Use of siramesine in the treatment of cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210208